Tobacco Approach Avoidance Training for Adolescent Smokers-2

Conditions

Tobacco Use Disorder

Trial Phase

Phase 2

Trial Purpose and Description

Trial Purpose

This is a two part study. In Study 2, smokers who want to quit smoking will participate in a 4 week smoking cessation program combining weekly cognitive behavioral therapy (CBT) with weekly regular-AAT or placebo-AAT training. We hypothesize that adolescent smokers will exhibit stronger approach tendencies towards smoking-related stimuli in the tobacco Approach Avoidance Training (AAT) task when compared with nonsmokers and that adolescent smokers who are trained to avoid smoking related stimuli using the AAT will avoid tobacco approach tendencies in the AAT test trials and the Implicit Association Task, when compared to adolescent smokers who are not exposed to AAT training. We also hypothesize that adolescent smokers who are trained to avoid tobacco in a training AAT in combination with CBT will have better abstinence rates compared to those who receive placebo AAT training with CBT.



Participation Guidelines

Age:
13 Years - 18 Years
Gender:
Both

Eligibility Criteria


Inclusion Criteria:

- Inclusion Criteria:

- Between ages 13-18 years

- Able to read and write in English.

- Smokers: Smoking 5 or more cigarettes daily for at least 6 months; Baseline urine
cotinine levels > 500 ng/ml

- Nonsmokers: Never smokers; Baseline urine cotinine levels < 50 ng/ml

Exclusion Criteria:

- Current criteria for dependence on another psychoactive substance

- Current diagnosis of psychosis, major depression or panic disorder

- Regular use of any psychoactive drugs including anxiolytics and
antidepressants unless the medication has been taken consistently for 2 months, is
currently being monitored by a physician, and the condition for which the medication
is taken is considered to be stable

- Pregnant or lactating girls, based on self report.
Sponsor:
VU University of Amsterdam
Yale University
Dates:
May 2012
Last Updated:
January 17, 2014
Study HIC#:
1103008127

Clinicaltrials.gov ID: NCT01625637